NCT00171873

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Carmen Schade-Brittinger · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut

Conditions

• Neuroendocrine Tumors

Interventions

Type	Name	Description
DRUG	Octreotide LAR (Long-acting release)	30 mg intramuscularly every 28 days
DRUG	Placebo	Sodium chloride intramuscularly every 28 days

Timeline

• Start date: 2001-09-01
• Primary completion: 2008-06-01
• Completion: 2013-12-01
• First posted: 2005-09-15
• Last updated: 2020-03-26
• Results posted: 2011-03-28

Locations

10 sites across 1 country: Germany